New Cancer Drug Hope

AstraZeneca has been collaborating with researchers who detected a potential Aurora B inhibitor.

Photo: New Cancer Drug Hope

A scientific paper, published in 2003 highlighted the potential success of targeting Aurora B, in the hope of developing a new class of drugs to inhibit this enzyme.
Aurora A and B are a type of enzyme known as protein kinases; they modify other proteins by chemically adding phosphate groups to them. In cancer, both these protein kinases are ‘over-expressed’.
At the Faculty of Life Sciences, University of Manchester, researchers have been studying a chemical that blocks, or inhibits, the catalytic actions of Aurora B and it has effectively killed cancer cells in lab grown cultures. ‘The first compounds were designed to inhibit a related enzyme called Aurora A,’ said Dr Stephen Taylor, who leads the research team. ‘Our research has shown that inhibiting Aurora B is a far more successful method of killing cancer cells. We’ve been strongly encouraged by these latest results.’

The research - published in the Journal of Cell Science - will be of interest to many other scientists looking at Aurora inhibitors (currently over 10 companies are involved in Aurora cancer research).
Although effective, many current cancer drugs are toxic. However, early clinical trials of Aurora-B drug’s toxicity have shown mild but not major adverse effects to patients. The next stage of trials to test its effectiveness is likely to begin soon.
The first results from the Phase I clinical trials using Aurora inhibitors were presented at the American Society for Clinical Oncology conference in Atlanta, in June

14.11.2006

Read all latest stories

Related articles

Photo

Alcohol ups colon cancer risk

Denmark - Regular drinkers significantly increase their risk of rectal cancer, but that risk is reduced if wine makes up a third or more of weekly consumption, according to research carried out by…

Photo

ECCO 15 and 34th ESMO Multidisciplinary Congress unites European Oncology

The first joint congress ECCO 15 - ESMO 34 of the European CanCer Organisation (ECCO) and the European Society for Medical Oncology (ESMO) is taking place this week in Berlin. It is the only…

New European Academy of Cancer Sciences founded

A new initiative designed to inform and educate policymakers at national, European, and global level about the needs of the oncology community was launched at Europe's largest cancer congress, ECCO…

Related products

Beckman Coulter – phi (Prostate Health Index)

Immunochemistry

Beckman Coulter – phi (Prostate Health Index)

Beckman Coulter, Inc.
Eppendorf – Mastercycler nexus X2

Research Use Only (RUO)

Eppendorf – Mastercycler nexus X2

Eppendorf AG
i-Solutions Health – LabCentre

LIS, Middleware, POCT

i-Solutions Health – LabCentre

i-SOLUTIONS Health GmbH
Medat – Laboratory Information System

LIS, Middleware, POCT

Medat – Laboratory Information System

Medat Computer-Systeme GmbH
Noras – Uni-Lift Prostate Intervention Device

MRT Coils

Noras – Uni-Lift Prostate Intervention Device

NORAS MRI products GmbH
Sarstedt – Low DNA Binding Micro Tubes

Research Use Only (RUO)

Sarstedt – Low DNA Binding Micro Tubes

SARSTEDT AG & CO. KG